Innovation in pharma isn’t just about molecules and machinery; it’s powered by people. Visionaries, disruptors, and dedicated minds drive the next wave of medicine, transforming bold ideas into life-changing therapies for patients around the world.

In this episode of In Combination, host Tom von Gunden combines the perspectives of three executives at Revolo Biotherapeutics – CEO Woody Bryan,

MindMed recently announced that the first patient has been dosed in its phase 3 Emerge study evaluating MM120 ODT for treatment of major depressive disorder (MDD). MM120 ODT is a proprietary, pharmaceutically optimized form of lysergic acid diethylamide (LSD).

CAMP4 Therapeutics is targeting regulatory RNA, whose role in gene expression was first described by co-founder and MIT Professor Richard Young.

Cue applied technology it initially tested in the treatment of cancers to the development of CUE-501. The idea is to make B cells appear as if they are infected with a virus such as cytomegalovirus or SARS-CoV-2.

Here’s how real scientists are effectively preparing to battle fungus today.

CorVista is bringing AI to bear on cardiac diagnostics, helping hospitals and doctors identify who need the most care.

John Kane, MD, shared new positive phase 2 data on N-methyl amisulpride (LB-102) for the treatment of patients with acutely exacerbated schizophrenia at the 2025 Annual Congress of the Schizophrenia International Research Society.